ArticlePloS one2026
Integrated NEK7-inflammasome and platelet transcriptomic signature generates mechanistic hypotheses in heart failure.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe relationship between NEK7-NLRP3 inflammasome activation and elevated platelet activity in the progression of heart failure (HF) is not well understood. Additionally, a comprehensive gene network linking these processes to cardiac fibrosis has not been established. Our study aimed to explore the transcriptomic associations between NEK7-inflammasome, platelet activation and cardiac fibrosis in heart failure (HF), and to generate pathogenic hypotheses.
methodsWe integrated bulk RNA-Seq (GSE116250, GSE57338) and scRNA-Seq (GSE183852) data from human HF samples. Through differential expression analysis, WGCNA, and machine learning techniques (LASSO and SVM-RFE), we identified key genes. A candidate diagnostic nomogram was subsequently developed and internally validated. We also conducted functional enrichment and immune infiltration analyses, and molecular docking studies. Key findings were explored in an angiotensin II-induced murine HF model using quantitative PCR.
resultsWe identified a novel four-gene signature, TIMP2, COL16A1, MDK, and ISLR, that shows co-expression patterns with NEK7 and platelet‑activation‑related gene sets. These genes were significantly upregulated in human HF tissues and showed similar expression trends in murine hearts, although ISLR exhibited a non-significant increase. A preliminary discrimination model based on these genes showed preliminary discriminatory efficacy in the training cohort (AUC = 0.993), however, this model requires further validation in prospective, multi-center cohorts before any clinical application can be considered. Functional enrichment analysis indicated their synergistic involvement in the TGF-β signaling pathway. Immune profiling underscored a correlation with CD56dim natural killer cell infiltration, identifying fibroblasts as the primary expressors of these genes. Pseudotime trajectory analysis illustrated dynamic expression patterns during fibroblast activation, and potential therapeutic compounds, such as β-Heparin and WZ4002, were predicted via molecular docking.
conclusionThis study introduces a novel fibro-inflammatory gene module linked to NEK7-mediated inflammation, platelet activation, and TGF-β signaling in HF. These findings generate integrated mechanistic hypotheses for HF pathogenesis and provide a foundation for subsequent diagnostic and mechanistic explorations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.